上海朗昇生物科技

Lumsun Biotech is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative gene therapies for ophthalmic diseases. The company focuses on Adeno-Associated Virus (AAV) vector technology to address unmet medical needs in genetic blindness and common retinal disorders. Its lead candidate, LX101, is a gene therapy targeting RPE65-mediated Leber Congenital Amaurosis (LCA2) and has entered clinical trials following IND approval. Lumsun's pipeline also includes treatments for wet age-related macular degeneration and diabetic macular edema. By leveraging its proprietary AAV platform, the company aims to provide long-lasting therapeutic solutions for patients with vision-threatening conditions.